Risks for sudden cardiac and undetermined cause of death among people with HIV in the REPRIEVE primary cardiovascular prevention trial
Christopher R. deFilippi, Steve Grinspoon(Harvard University), Heather J. Ribaudo(Cancer Research And Biostatistics), Carl J. Fichtenbaum(Cancer Research And Biostatistics), Sarah M Chu(Harvard University), Sophia Zhao(Austin Health), Cornelius Van Dam(Cone Health), Kayla Paradis(Cancer Research And Biostatistics), Pamela S. Douglas(Duke University), Michael T. Lu(Cancer Research And Biostatistics), José Henrique Pilotto(Universidade Iguaçu), Isabelle R. Weir(Cancer Research And Biostatistics), Carlos Malvestutto(The Ohio State University Wexner Medical Center), Gerald S. Bloomfield, Marissa R Diggs(Harvard University), Judith S. Currier(University of California, Los Angeles), Rodger D. MacArthur(Augusta University), Kristen Marks(Cornell University), Judith A. Aberg(Icahn School of Medicine at Mount Sinai), Stephen Wiviott(Brigham and Women's Hospital), Markella V. Zanni(Harvard University), Aya Awwad(Harvard University), Aimee Wilkin(Wake Forest University)
Cited by 3
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k